Oncolytics’ Reolysin in new trial

The Children’s Oncology Group, in collaboration with the National Institutes of Health, intends to conduct a Phase 1 clinical trial of Oncolytics Biotech’s (TSX:ONC; NASDAQ:ONCY) Reolysin drug in combination with cyclophosphamide in pediatric patients aged three-to-21 with relapsed or refractory solid tumours. The primary objectives of the trial include estimating maximum tolerated dose, and defining [...]

Oncolytics in $25 million bought deal

A group of underwriters have agreed to purchase 5.44 million units of Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY) in a bought deal at a price of $4.60 each for total proceeds of about $25 million. Each unit consists of one common share and one-half of a warrant, with each whole warrant entitling the holder to buy an [...]

Canadians’ data heading to ASCO

Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8.  He expects: · AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, [...]

Oncolytics ready for final step with Reolysin

After a 10-year journey, Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY ) is ready to take the final clinical step with its sole Reolysin drug as a treatment for a broad range of cancers. “Our product has really shown a breadth of activity in a wide variety of cancers that we had hoped it would way back when [...]